CN1845756A - 用于治疗疱疹感染的方法和组合物 - Google Patents

用于治疗疱疹感染的方法和组合物 Download PDF

Info

Publication number
CN1845756A
CN1845756A CNA2004800253052A CN200480025305A CN1845756A CN 1845756 A CN1845756 A CN 1845756A CN A2004800253052 A CNA2004800253052 A CN A2004800253052A CN 200480025305 A CN200480025305 A CN 200480025305A CN 1845756 A CN1845756 A CN 1845756A
Authority
CN
China
Prior art keywords
herpes
mammal
compositions
immunoglobulin
iga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800253052A
Other languages
English (en)
Chinese (zh)
Inventor
U·贝茨
K－P·拉特克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of CN1845756A publication Critical patent/CN1845756A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2004800253052A 2003-09-05 2004-09-02 用于治疗疱疹感染的方法和组合物 Pending CN1845756A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/656,781 US6984492B2 (en) 2003-09-05 2003-09-05 Methods and compositions for treating herpes infections
US10/656,781 2003-09-05

Publications (1)

Publication Number Publication Date
CN1845756A true CN1845756A (zh) 2006-10-11

Family

ID=34226428

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800253052A Pending CN1845756A (zh) 2003-09-05 2004-09-02 用于治疗疱疹感染的方法和组合物

Country Status (13)

Country Link
US (3) US6984492B2 (enExample)
EP (1) EP1663309A2 (enExample)
JP (1) JP2007504268A (enExample)
KR (1) KR20060107509A (enExample)
CN (1) CN1845756A (enExample)
AU (1) AU2004272001A1 (enExample)
BR (1) BRPI0414139A (enExample)
CA (1) CA2537360A1 (enExample)
IL (1) IL173805A0 (enExample)
NO (1) NO20061184L (enExample)
NZ (1) NZ546303A (enExample)
WO (2) WO2005023303A1 (enExample)
ZA (1) ZA200602738B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用
CN106488931A (zh) * 2014-06-26 2017-03-08 海德堡免疫疗法有限公司 抗hsv抗体的局部应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2248825T3 (da) 2009-05-04 2013-01-02 Ribovax Biotechnologies Sa Antigenbindingsfragment af et antistof til anvendelse i behandling og diagnosticering af okulare sygdomme
WO2013023362A1 (zh) * 2011-08-16 2013-02-21 深圳市卫武光明生物制品有限公司 静注巨细胞病毒人免疫球蛋白及其制备方法
US10829543B2 (en) 2012-10-29 2020-11-10 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
US10100102B2 (en) 2012-10-29 2018-10-16 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
CA2942166A1 (en) * 2014-03-03 2015-09-11 Albert Einstein College Of Medicine, Inc. Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
WO2017083681A1 (en) 2015-11-13 2017-05-18 The University Or North Carolina At Chapel Hill Optimized crosslinkers for trapping a target on a substrate
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3877406A1 (en) * 2018-11-08 2021-09-15 The Board of Trustees of the University of Illinois Treatment and diagnosis of autoantibody-mediated eye diseases
WO2021207348A1 (en) * 2020-04-07 2021-10-14 Albert Einstein College Of Medicine Method of treating and preventing ocular disease with hsv-2 delta gd

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617379A (en) * 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
US4717564A (en) * 1985-11-07 1988-01-05 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US4665159A (en) * 1985-11-07 1987-05-12 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US5258177A (en) * 1991-12-10 1993-11-02 Alpha Therapeutic Corporation IgA preparation and process of making the same
RU2051054C1 (ru) 1992-04-14 1995-12-27 Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского Способ получения препарата противогерпетического иммуноглобулина человека
US5681565A (en) 1993-01-12 1997-10-28 Medical Sciences Research Institute Methods and compositions for passive immunotherapy
WO1994015640A1 (en) 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
AU6968098A (en) * 1997-04-15 1998-11-11 Advanced Viral Research Corp. Topical treatment of skin diseases and eye afflictions
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106488931A (zh) * 2014-06-26 2017-03-08 海德堡免疫疗法有限公司 抗hsv抗体的局部应用
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用

Also Published As

Publication number Publication date
IL173805A0 (en) 2006-07-05
US20050053605A1 (en) 2005-03-10
NZ546303A (en) 2009-03-31
KR20060107509A (ko) 2006-10-13
JP2007504268A (ja) 2007-03-01
US20090232798A1 (en) 2009-09-17
ZA200602738B (en) 2008-06-25
CA2537360A1 (en) 2005-03-24
WO2005025617A2 (en) 2005-03-24
US6984492B2 (en) 2006-01-10
WO2005023303A1 (en) 2005-03-17
WO2005025617A3 (en) 2005-05-26
NO20061184L (no) 2006-06-01
AU2004272001A1 (en) 2005-03-24
US20060198848A1 (en) 2006-09-07
BRPI0414139A (pt) 2006-10-31
EP1663309A2 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
US20090232798A1 (en) Methods and compositions for treating herpes infections
CA1057195A (en) Preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use
RU2587061C2 (ru) Способы лечения аллергических заболеваний
EP0614369B1 (en) Pharmaceutical dipeptide compositions and methods of use thereof
RU2071323C1 (ru) Противовирусный препарат "полирем"
JPH06507386A (ja) 治療用ペプチド
CA2107460A1 (en) Pharmaceutical dipeptide compositions and methods of use thereof
CN115998761B (zh) 一种抗过敏鼻炎组合物及其制备方法和应用
US10548870B2 (en) Method for treating multiple sclerosis
JP4580479B2 (ja) 抗ｈｉｖ感染症剤
CN1098687C (zh) 氨基嘌呤抗病毒剂在治疗和预防潜伏性疱疹病毒感染中的用途
NO322176B1 (no) Anvendelse av pox inducere omfattende en kombinasjon av henholdsvis flere pox virus og parapox virus for fremstilling av medikamentet for prefinal tumorterapi for a lindre smerte og optimalisere velbefinnende til pasienter.
MXPA06002585A (en) Methods and compositions for treating herpes infections
AU621110B2 (en) The use of the thiazole derivative tiprotinod for the preparation of an agent for the therapy of virus infections
RU2847403C1 (ru) Способ лечения иммунодефицита внутривенным введением аминодигидрофталазиндиона натрия
WO1996029092A1 (en) Corneal vascularization inhibitor
JP3266254B2 (ja) ヘルペス関連疾患の治療方法および組成物
US4230725A (en) Antiviral agent
RU2180238C1 (ru) Биологический препарат для профилактики и лечения желудочно-кишечных и респираторных болезней телят
JPH10330257A (ja) 眼局所用サイトカイン産生抑制剤
RU2249465C1 (ru) Способ лечения и профилактики иммунодефицитных состояний и заболеваний, связанных с бактериальной или вирусной агрессией
Nicholson Antiviral Therapy: Respiratory Infections, Genital Herpes, and Herpetic Keratitis
RU2435606C1 (ru) Лекарственное средство, обладающее противовирусными свойствами
RU2293562C2 (ru) Использование аминопуриновых противовирусных соединений для лечения и профилактики латентных инфекций, вызванных вирусом герпеса
JPH0977684A (ja) 自己免疫抑制性ｔ細胞の活性化剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Applicant

Correct: Talecris Biotherapeutics Inc.

False: Bayer Healthcare LLC

Number: 41

Volume: 22

CI02 Correction of invention patent application

Correction item: Applicant

Correct: Talecris Biotherapeutics Inc.

False: Bayer Healthcare LLC

Number: 41

Page: The title page

Volume: 22

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: BAYER HEALTHCARE CO., LTD. TO: TAYLOR KRIS BIO-THERAPEUTICS CO.

ERR Gazette correction

Free format text: CORRECT: APPLICANT; FROM: BAYER HEALTHCARE CO., LTD. TO: TAYLOR KRIS BIO-THERAPEUTICS CO.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20061011